Noninvasive Assessment of Liver Fibrosis in NAFLD
Clinical Gastroenterology and Hepatology · 2023-07 · 21 (8) · 2026-2039
DOI: 10.1016/j.cgh.2023.03.042 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023-07. Verfasst von Arun J Sanyal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmon…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Elasticity Imaging Techniques, Liver Neoplasms. Die Arbeit wurde bisher 161-mal zitiert (Crossref) und nennt 84 Literaturangaben.
Abstract (Originalsprache)
Nonalcoholic fatty liver disease (NAFLD) has emerged as a leading cause of liver-related morbidity and mortality worldwide, afflicting approximately a billion individuals. NAFLD is a slowly progressive disease that may evolve in a subset of patients toward cirrhosis, hepatocellular carcinoma, and end-stage liver disease. Liver fibrosis severity is the strongest predictor of clinical outcomes. The emergence of effective therapeutics on the horizon highlights the need to identify among patients with NAFLD, those with severe fibrosis or cirrhosis, who are the most at risk of developing complications and target them for therapy. Liver biopsy has been the reference standard for this purpose. However, it is not suitable for large-scale population evaluation, given its well-known limitations (invasiveness, rare but severe complications, and sampling variability). Thus, there have been major efforts to develop simple noninvasive tools that can be used in routine clinical settings and in drug development. Noninvasive approaches are based on the quantification of biomarkers in serum samples or on the measurement of liver stiffness, using either ultrasound- or magnetic resonance-based elastography techniques. This review provides a roadmap for future development and integration of noninvasive tools in clinical practice and in drug development in NAFLD. We discuss herein the principles for their development and validation, their use in clinical practice, including for diagnosis of NAFLD, risk stratification in primary care and hepatology settings, prediction of long-term liver-related and non-liver-related outcomes, monitoring of fibrosis progression and regression, and response to future treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia. Electronic address: arun.sanyal@vcuhealth.org.
- UMR1149 (Center of Research on Inflammation), French Institute of Health and Medical Research, Université Paris Cité, Paris, France; Service d'Hépatologie, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy,…
- State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China; Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese Unive…
Zitieren
APA
Sanyal, A. J., Castera, L., & Wong, V. W. (2023). Noninvasive Assessment of Liver Fibrosis in NAFLD. Clinical Gastroenterology and Hepatology, 21(8), 2026-2039. https://doi.org/10.1016/j.cgh.2023.03.042
Vancouver
Sanyal AJ, Castera L, Wong VW. Noninvasive Assessment of Liver Fibrosis in NAFLD. Clinical Gastroenterology and Hepatology. 2023;21(8):2026-2039. doi:10.1016/j.cgh.2023.03.042
BibTeX
@article{Sanyal2023,
author = {Sanyal, Arun J and Castera, Laurent and Wong, Vincent Wai-Sun},
title = {Noninvasive Assessment of Liver Fibrosis in NAFLD},
journal = {Clinical Gastroenterology and Hepatology},
year = {2023},
volume = {21},
number = {8},
pages = {2026--2039},
doi = {10.1016/j.cgh.2023.03.042}
}
EUVIMED